1. Home
  2. REGN vs VST Comparison

REGN vs VST Comparison

Compare REGN & VST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REGN
  • VST
  • Stock Information
  • Founded
  • REGN 1988
  • VST 1882
  • Country
  • REGN United States
  • VST United States
  • Employees
  • REGN N/A
  • VST N/A
  • Industry
  • REGN Biotechnology: Pharmaceutical Preparations
  • VST Electric Utilities: Central
  • Sector
  • REGN Health Care
  • VST Utilities
  • Exchange
  • REGN Nasdaq
  • VST Nasdaq
  • Market Cap
  • REGN 59.5B
  • VST 65.2B
  • IPO Year
  • REGN 1991
  • VST N/A
  • Fundamental
  • Price
  • REGN $560.00
  • VST $209.77
  • Analyst Decision
  • REGN Buy
  • VST Strong Buy
  • Analyst Count
  • REGN 23
  • VST 9
  • Target Price
  • REGN $794.83
  • VST $199.44
  • AVG Volume (30 Days)
  • REGN 972.9K
  • VST 3.9M
  • Earning Date
  • REGN 10-30-2025
  • VST 11-06-2025
  • Dividend Yield
  • REGN 0.63%
  • VST 0.43%
  • EPS Growth
  • REGN 5.03
  • VST 383.82
  • EPS
  • REGN 39.67
  • VST 6.37
  • Revenue
  • REGN $14,214,200,000.00
  • VST $18,508,000,000.00
  • Revenue This Year
  • REGN N/A
  • VST $20.55
  • Revenue Next Year
  • REGN $4.86
  • VST $9.55
  • P/E Ratio
  • REGN $14.12
  • VST $32.91
  • Revenue Growth
  • REGN 5.38
  • VST 31.60
  • 52 Week Low
  • REGN $476.49
  • VST $79.03
  • 52 Week High
  • REGN $1,170.58
  • VST $216.85
  • Technical
  • Relative Strength Index (RSI)
  • REGN 46.27
  • VST 62.27
  • Support Level
  • REGN $552.98
  • VST $178.43
  • Resistance Level
  • REGN $570.76
  • VST $212.88
  • Average True Range (ATR)
  • REGN 15.16
  • VST 7.13
  • MACD
  • REGN -2.91
  • VST 1.95
  • Stochastic Oscillator
  • REGN 16.26
  • VST 90.97

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

About VST Vistra Corp.

Vistra Energy is one of the largest power producers and retail energy providers in the US. Following the 2024 Energy Harbor acquisition, Vistra owns 41 gigawatts of nuclear, coal, natural gas, solar, and energy storage assets. The proposed Lotus Partners acquisition would add 2.6 GW of natural gas generation. Its retail electricity business serves 5 million customers in 20 states, including almost a third of all Texas electricity consumers. Vistra emerged from the Energy Future Holdings bankruptcy as a stand-alone entity in 2016. It acquired Dynegy in 2018.

Share on Social Networks: